Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASF-1075 cream for anogenital lichen simplex chronicus pruritus
2006-005221-37Phase 2Terminated
- Sponsor
- Astion Pharma
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ASF-1075 in neurodermatitis (3 arms), sponsored by Astion Pharma. Primary endpoint: Pruritus after 3 weeks treatment compared with baseline. Started Nov 2006; status: terminated.
02
Drugs
ASF-1075
03
Conditions
neurodermatitis
Beyond the preview
Go deeper on 2006-005221-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005221-37.